CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗在复发/难治性成人 B-ALL 中的作用
英文原题：The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL.
查看英文原题
The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞治疗是近期治疗进展，已改变复发/难治性（R/R）B 急性淋巴细胞白血病（B-ALL）的管理方式。目前 FDA 已批准 2 种治疗 R/R B-ALL 的 CAR-T 产品：tisagenlecleucel 用于年龄 <26 岁患者，brexucabtagene autoleucel 用于年龄 ≥18 岁患者。本综述总结促成这两种产品获 FDA 批准的关键临床试验，并强调回应 CAR-T 细胞在快速演进的 R/R ALL 管理中应用相关关键问题的新兴数据，包括 CAR-T 与其他新型免疫治疗药物的最佳序贯顺序、CAR-T 后巩固和维持治疗的作用、目前正在临床开发的新型 CAR-T 构型，以及优化商业化 CAR-T 产品使用以改善患者结局的策略。
展开英文摘要原文
CAR T-cell therapy is a recent therapeutic advancement that has transformed the management of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). To date, there are 2 FDA-approved CAR-T products for R/R B-ALL: tisagenlecleucel in patients aged <26 years and brexucabtagene autoleucel in those aged 18 years.
This review summarizes the pivotal clinical trials that led to FDA approval of these 2 products and highlight emerging data addressing key questions pertinent to CAR-T utilization in the rapidly evolving landscape of R/R ALL management. These include optimal sequencing of CAR-T among other novel immunotherapeutic agents, the role of consolidation and maintenance following CAR-T, novel CAR-T constructs currently under clinical development, and strategies to optimize use of commercially available CAR-T products to improve patient outcomes.
论文信息
- 作者
- Othman T、Logan AC、Muffly L、Leonard J、Park J、Shah B、Aldoss I
- 单位
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.United States
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Journal of the National Comprehensive Cancer Network : JNCCN2024 Oct
- 原文标识
- PubMed 39413830 · DOI 10.6004/jnccn.2024.7065